# Nuclide record opp-dll3-imaging-sclc (opportunity). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/opportunities/opp-dll3-imaging-sclc/>
  a schema:CreativeWork ;
  nuclide:kind "opportunity" ;
  schema:identifier "opp-dll3-imaging-sclc" ;
  schema:name "DLL3 imaging for small-cell lung cancer"@en ;
  schema:alternateName "DLL3 PET"@en, "delta-like ligand 3 imaging"@en ;
  schema:description "A drug that attacks small-cell lung cancer through a protein called DLL3 is already approved, but there is no approved scan that shows whether a patient's tumours still carry that protein. Doctors decide from a single biopsy taken from one place, which cannot show what the rest of the disease is doing."@en ;
  schema:url <https://nuclide.cc/opportunities/opp-dll3-imaging-sclc/> ;
  schema:dateModified "2026-09-23"^^xsd:date ;
  schema:citation <https://pubmed.ncbi.nlm.nih.gov/38950555/>, <https://clinicaltrials.gov/study/NCT04199741>, <https://clinicaltrials.gov/study/NCT07677787>, <https://pubmed.ncbi.nlm.nih.gov/32745892/>, <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-tarlatamab-extensive-stage-small-cell-lung-cancer> ;
  nuclide:tag "theranostic gap", "companion diagnostic", "lung", "neuroendocrine" ;
  nuclide:related <https://nuclide.cc/isotopes/zr-89/>, <https://nuclide.cc/isotopes/ga-68/>, <https://nuclide.cc/isotopes/lu-177/> ;
  nuclide:indications <https://nuclide.cc/indications/sclc/> ;
  nuclide:technologies <https://nuclide.cc/technologies/immuno-pet/>, <https://nuclide.cc/technologies/pet-ct/> ;
  nuclide:targets <https://nuclide.cc/targets/dll3/> .